Mitral regurgitation (MR) has been associated with adverse outcomes after myocardial infarction (MI). Without structural valve disease, functional MR has been related to left ventricular (LV) remodeling and geometric deformation of the mitral apparatus. The aims of this study were to elucidate the mechanistic components of MR after high-risk MI and to identify predictors of MR progression during follow-up.
The Valsartan in Acute Myocardial Infarction Echo substudy prospectively enrolled 610 patients with LV dysfunction, heart failure, or both after MI. MR at baseline, 1 month, and 20 months was quantified by mapping jet expansion in the left atrium in 341 patients with good-quality echocardiograms. Indices of LV remodeling, left atrial size, and diastolic function and parameters of mitral valve deformation, including tenting area, coaptation depth, anterior leaflet concavity, annular diameters, and contractility, were assessed and related to baseline MR. The progression of MR was further analyzed, and predictors of worsening among the baseline characteristics were identified.
Tenting area, coaptation depth, annular dilatation, and left atrial size were all associated with the degree of baseline MR. Tenting area was the only significant and independent predictor of worsening MR; a tenting area of 4 cm 2 was a useful cutoff to identify worsening of MR after MI and moderate to severe MR after 20 months.
Increased mitral tenting and larger mitral annular area are determinants of MR degree at baseline, and tenting area is an independent predictor of progression of MR after MI. Although LV remodeling itself contributes to ischemic MR, this influence is directly dependent on alterations in mitral geometry.
Mitral regurgitation (MR) is a powerful predictor of adverse prognosis after myocardial infarction (MI) with increased risk for death and heart failure and provides incremental prognostic information over conventional known clinical and echocardiographic predictors of risk after MI. Moreover, progression of MR in the chronic phase after MI is associated with an increased likelihood of cardiovascular morbidity. Although MR can be caused by discrete papillary muscle disruption after MI, this occurs rarely. Rather, the majority of cases of post-MI MR develop in the absence of structural mitral disease and are caused as a result of apical and posterior papillary muscle (PPM) displacement with consequent mitral valve tethering and incomplete valve closure due to the restriction of leaflet motion, resulting in functional MR. In addition, dilatation and loss of contraction of the mitral annulus contribute to increased valvular malcoaptation, therefore increasing the severity of MR.
To understand the mechanistic components and the echocardiographic determinants of baseline MR as well as the progression of MR during follow-up after MI, we studied patients enrolled in the Valsartan in Acute Myocardial Infarction (VALIANT) Echo substudy. We hypothesized that the effects of left ventricular (LV) remodeling on mitral geometry deformation are the dominant factors underlying the genesis of post-MI MR and its evolution.
VALIANT was designed to test the efficacy and safety of long-term treatment with valsartan, captopril, and their combination after acute MI (between 0.5 and 10 days previously) complicated by clinical or radiologic signs of heart failure, evidence of LV systolic dysfunction (ejection fraction [EF] ≤ 0.35 on echocardiography or contrast angiography and ≤ 0.40 on radionuclide ventriculography), or both. The main criteria for exclusion were a previous intolerance or contraindication to an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker and another disease known to limit life expectancy severely. A total of 14,703 patients were eligible for this study.
The VALIANT Echo substudy was designed prospectively to test the hypothesis that valsartan, either alone or in combination with captopril, could attenuate progressive LV enlargement or improve LV function to a greater extent than captopril alone. Entry criteria were identical to those for the main VALIANT study. All the clinical sites participating in the main VALIANT study were invited to enroll patients in the VALIANT Echo substudy. From 94 clinical sites in 13 different countries, a total of 610 echocardiographic studies were sent to the core laboratory at Brigham and Women’s Hospital, where they were reviewed for quality. Baseline characteristics of patients enrolled in the VALIANT Echo substudy were similar to those who were not, as previously reported. Patients with echocardiographic images of insufficient quality, absence of color-flow Doppler images, or color-flow Doppler images of insufficient quality were excluded from the VALIANT MR Echo cohort, and the final population consisted of 496 patients. For 341 of these patients, it was possible to prospectively evaluate the evolution of MR after 20 months. Of the others, 84 patients died, and for 71 patients, the 20-month echocardiographic study was not available or had MR color-flow Doppler images of insufficient quality.
Echocardiographic examinations were performed at a mean of 4.9 ± 2.5 days after MI (before randomization), at 1 month, and at 20 months. The median follow-up time was 24.7 months. The majority of patients were hemodynamically stable at the time of the echocardiographic assessment. Except for minor differences, the VALIANT MR Echo cohort was similar to the overall VALIANT cohort. Patients provided informed consent for inclusion in the VALIANT Echo substudy, and the protocol was approved by the appropriate institutional review boards.
Baseline Clinical Characteristics
The following baseline clinical characteristics were analyzed in the VALIANT MR Echo cohort: age; race; gender; blood pressure; heart rate; body mass index; Killip class; history of MI, hypertension, diabetes, heart failure, or smoking; anterior or inferior MI site; Q-wave or non Q-wave MI type; reperfusion therapy with thrombolysis or primary percutaneous transluminal coronary intervention; previous therapy with angiotensin-converting enzyme inhibitors; and treatment with aspirin, β-blockers, or statins at randomization.
All echocardiographic studies were analyzed in the core laboratory at Brigham and Women’s Hospital. Echocardiograms from videotape were digitized, and analyses were performed with the use of quantitative analysis software.
LV endocardial borders were manually traced at end-diastole and end-systole in apical four-chamber and two-chamber views. LV volumes and EF were derived according to the modified biplane Simpson’s method. The LV sphericity indices were calculated as the ratio of LV volumes (end-diastolic and end-systolic) and the volume of a sphere with a diameter equal to the LV (end-diastolic and end-systolic) long axis (sphericity index = 6 V /π L 3 ). LV volumes and sphericity indices were considered parameters of global LV remodeling.
MR was assessed using a semiquantitative method tracing the area of the maximum systolic jet expansion in the left atrium in four-chamber and two-chamber views. Left atrial (LA) area was also measured in the same frame with the maximum regurgitant jet. According to current guidelines, color-flow Doppler images of regurgitant jet were acquired using a Nyquist limit (aliasing velocity) of 50 to 60 cm/sec and a color gain that just eliminated random color speckle from nonmoving regions. All the color-flow Doppler images used the same color map (red for flow toward the transducer and blue for flow away from the transducer, with the shade of color indicating velocity up to the Nyquist limit). The MR jet comprised a mosaic of many colors indicating turbulence. The protocol specified that the same ultrasound instruments, transducers, and settings of the baseline acquisition should be used for the follow-up examinations.
MR was then categorized by calculating MR jet/LA area ratio. MR was considered mild when the regurgitant jet area occupied >5% and <20% of LA area, moderate when regurgitant jet area occupied >20% and <40% of LA area, and severe when regurgitant jet area occupied >40% of LA area. The presence of an eccentric jet raised the grade of MR by one degree on the basis of evidence of reduced color-flow jet areas due to a loss of momentum in jets adjacent to chamber walls. An eccentric jet was defined as a regurgitant jet, which impinges on the LA wall immediately beyond the mitral valve.
The following indices of geometric mitral valve deformation were measured from parasternal long-axis view ( Figure 1 ): tenting area, defined as the area enclosed between the annular plane and the mitral leaflets in mid-systole; coaptation depth, defined as the distance between leaflet coaptation and the mitral annular (MA) plane in mid-systole ; anterior mitral leaflet (AML) shape, visually assessed as concave or convex configuration of the leaflet toward the left atrium in mid-systole (with convexity representing the normal condition and concavity an expression of tethering of mitral valve leaflets) ; and AML diastolic restricted motion, defined as maximal opening angle between the AML and the annulus equal or inferior to the angle between the annulus and a line connecting the PPM head and intervalvular fibrosa. Moreover, maximum and minimum MA diameters were measured in four-chamber and two-chamber views at end-diastole and end-systole, and MA areas were calculated using an ellipsoid assumption (MA area = d 1 × d 2 × π/4); MA contraction was calculated as the ratio of the difference between MA end-diastolic area and MA end-systolic area to MA end-diastolic area.
Outward displacement of the PPM, an index of global and local LV remodeling, was quantified by annular-papillary distance, defined as the distance between the PPM head and intervalvular fibrosa in the parasternal long-axis view in systole. Local remodeling of the LV wall at the PPM attachment was evaluated by the presence of thinning or bulging of inferior wall.
LA volume was measured by the biplane area-length method from apical four-chamber and two-chamber views at end-systole, and LA volume was indexed to body surface area. Diastolic function was evaluated by transmitral pulsed-wave Doppler from the apical four-chamber view, and a restrictive pattern was defined as E/A peak wave ratio > 2 and deceleration time < 140 msec. All the echocardiographic measurements were repeated in three separate cardiac cycles.
Baseline continuous data are expressed as mean ± SD, and categorical variables are expressed as absolute numbers of patients and percentages. At baseline, patients were divided into three groups according to MR degree (none, mild, and moderate to severe), and a nonparametric test derived from Wilcoxon’s rank-sum test was used to examine trends in baseline clinical and echocardiographic characteristics. During 20 months of follow-up, the patients were divided into a group with no MR changes or improvement and a group with MR increase of at least one grade; clinical and echocardiographic characteristics in these two groups were compared using t tests for continuous variables and χ 2 tests for discrete variables. Backward and forward stepwise multivariate linear regression analysis was performed to assess the baseline predictors of baseline MR jet/LA area ratio and the overall change in MR jet/LA area ratio, using two different models. The first model considered only echocardiographic variables, while the second one added the clinical variables that were significant by univariate analyses to echocardiographic variables. The relationship between baseline tenting area and MR severity at baseline and after 20 months was tested using a logistic regression. The cutoff value of tenting area that was most sensitive and specific in predicting MR was determined by means of receiver operating characteristic curve analysis. Change in MR jet/LA area was compared with changes in LV and LA remodeling over time using Pearson’s correlations.
Intraobserver reproducibility was tested in 15% of patients randomly selected, in a blinded fashion. The mean differences and the SD of the differences between measurements were calculated (Bland-Altman method), and variability was calculated as the SD of the difference divided by the mean measurement. The overall coefficients of variability of the continuous echocardiographic parameters were as follows: MR area, 1%; LA volume index, 5.4%; LV end-diastolic volume, 8.3%; diastolic sphericity index, 6.2%; annular-papillary distance, 7.2%; tenting area, 6%; coaptation depth, 6.4%; and MA diastolic area, 5.5%. All P values were two sided; P values < .05 were considered statistically significant. All statistical analyses were performed using Stata version 8 (StataCorp LP, College Station, TX).
Among the 496 patients with baseline echocardiographic evaluations of MR, 231 patients (46%) did not have MR, 202 patients (41%) had mild MR, and 63 patients (13%) had moderate to severe MR. MR severity at baseline was associated with older age ( P < .001), female sex ( P < .001), prior MI ( P < .01), hypertension ( P = .02), diabetes ( P < .01), heart failure ( P = .001), and non-Q-wave MI ( P = .01).
Echocardiographic measures of ventricular and mitral geometry associated with MR degree are shown in Table 1 . Patients with higher MR degrees had worse LV global remodeling, with higher LV volumes and sphericity indices and lower EFs ; moreover, they had greater annular-papillary distances and were more likely to have worse local remodeling of the inferior wall. MR severity was also associated with increased geometric deformation of the mitral apparatus (higher tenting area, coaptation depth, and MA areas with lower MA contraction; presence of diastolic restricted motion and concavity of the AML). Higher MR degree was associated with larger left atria and restrictive filling. Twenty-five patients presented at baseline with eccentric jets. Considering only the 471 patients (95%) with central jets, all the considered echocardiographic parameters were still significant determinants of higher MR degree, with the exception of a restrictive diastolic pattern and restrictive motion of the mitral leaflet.
|Variable||Baseline MR degree||P for trend|
|None or trace ( n = 231 [46%])||Mild ( n = 202 [41%])||Moderate to severe ( n = 63 [13%])|
|LV EDV (mL)||112 ± 28||123 ± 29||139 ± 43||<.001|
|LV ESV (mL)||67 ± 20||77 ± 23||88 ± 33||<.001|
|LV EF (%)||40 ± 5||38 ± 6||38 ± 7||.001|
|Sphericity index (%)|
|Diastolic||42 ± 10||47 ± 10||50 ± 10||<.001|
|Systolic||36 ± 10||40 ± 11||43 ± 9||<.001|
|Annular-papillary distance (cm)||3.8 ± 0.6||4.1 ± 0.6||4.1 ± 0.5||.028|
|Thinning-bulging of inferior wall||15%||24%||29%||.011|
|Mitral valve geometry|
|Tenting area (cm 2 )||3.8 ± 0.7||4.2 ± 0.7||4.1 ± 0.8||<.001|
|Coaptation depth (cm)||1.5 ± 0.2||1.6 ± 0.2||1.6 ± 0.2||.008|
|Diastolic area (cm 2 )||7.1 ± 1||8.2 ± 1.2||9.6 ± 1.4||<.001|
|Systolic area (cm 2 )||5.5 ± 0.9||6.5 ± 1.2||7.7 ± 1.4||<.001|
|Annular contraction (%)||22 ± 6||21 ± 6||20 ± 6||.004|
|Concavity of AML||31%||35%||56%||.003|
|Diastolic restricted motion||14%||19%||36%||.003|
|Diastolic function and left atrium|
|LA volume index (mL/m 2 )||20 ± 5||26 ± 7||35 ± 10||<.001|
In a multivariate model adjusted for echocardiographic variables, the degree of baseline MR was related to parameters of altered mitral valve geometry (tenting area, P = .009; coaptation depth, P = .046; MA diastolic area, P < .001) and larger left atria ( P = .016); LV remodeling indices were not independently associated with baseline MR degree. By adding to the previous multivariate model the clinical variables that were significant by univariate analyses, tenting area, coaptation depth, MA diastolic area, and LA volume index remained independently associated with degree of baseline MR severity ( P = .006, P = .011, P < .001, and P = .013, respectively), while female sex was the only clinical factor independently associated with MR degree ( P = .006).
In 341 patients with completed echocardiographic follow-up, MR worsened by one degree in 78 patients (23%) and by two degrees in 10 patients (3%) at 20 months compared with baseline. Forty-seven patients (14%) experienced improvements in MR by one degree, and in 206 patients (60%), the presence and severity of MR were unchanged. At 20 months, 150 patients (44%) had no detectable MR, 139 patients (41%) had mild MR, and 52 patients (15%) had moderate to severe MR.
During the first month after MI, early MR progression was significantly greater than late progression during the remaining follow-up period (1.9 ± 0.3% vs 0.4 ± 0.3% increase in MR jet/LA area ratio during the first month and between 1 and 20 months, respectively, P < .001). Patients with worsening by one or more MR degrees during the first month after MI experienced the greatest increase in MR jet/LA area ratio during follow-up (11.4 ± 9.3% vs 0.01 ± 6.7%, P < .001) and were more likely to have moderate or greater MR degrees at 20 months (69% vs 31%, P < .001).
Among the clinical baseline characteristics, only systolic blood pressure was significantly increased in the group of patients who developed worsening in MR degree after 20 months (124 ± 15 vs 119 ± 14 mm Hg, P = .011). There was no difference in degree of MR worsening by treatment group.
Echocardiographic baseline characteristics according to worsening versus unchanged or improved MR degree after 20 months are shown in Table 2 . Greater baseline tenting area and coaptation depth predicted MR progression in univariate analyses. Tenting area remained a predictor of MR progression in multivariate analyses, in models including either echocardiographic measures or a combination of echocardiographic and clinical variables ( P = .023). Adding 1-month MR data to this model, both tenting area and worsening by at least one degree during the early phase after MI were significant and independent predictors ( P = .018 and P < .001, respectively). Sixteen of these patients presented with eccentric jets. Considering only the 325 patients (95%) with central jets, tenting area and coaptation depth were confirmed to be predictors of worsening MR.
|Variable||Overall population |
( n = 341)
|No MR changes or improvement |
( n = 253 [74%])
|Worsening MR of at least one grade |
( n = 88 [26%])
|LV EDV (mL)||118 ± 30||118 ± 32||117 ± 26||.740|
|LV ESV (mL)||72 ± 24||72 ± 25||71 ± 20||.592|
|LV EF (%)||39 ± 6||39 ± 6||39 ± 6||.684|
|Sphericity index (%)|
|Diastolic||44 ± 11||44 ± 10||45 ± 11||.748|
|Systolic||38 ± 11||37 ± 10||39 ± 13||.l28|
|Annular-papillary distance (cm)||3.9 ± 0.6||3.8 ± 0.5||4.0 ± 0.6||.101|
|Thinning-bulging of inferior wall||18%||19%||16%||.331|
|Mitral valve geometry|
|Tenting area (cm 2 )||3.9 ± 0.6||3.8 ± 0.6||4.2 ± 0.7||<.001|
|Coaptation depth (cm)||1.6 ± 0.2||1.5 ± 0.2||1.6 ± 0.2||.032|
|Diastolic area (cm 2 )||7.8 ± 1.3||7.8 ± 1.3||7.7 ± 1.1||.448|
|Systolic area (cm 2 )||6.1 ± 1.2||6.1 ± 1.3||6.0 ± 1.1||.283|
|Annular contraction (%)||22 ± 6||22 ± 6||22 ± 6||.275|
|Concavity of AML||35%||35%||37%||.795|
|Diastolic restricted motion||18%||17%||21%||.459|
|Diastolic function and left atrium|
|LA volume index (mL/m 2 )||23 ± 7||23 ± 8||22 ± 7||.180|